Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

Category Primary study
JournalCancer Research
Year 2022
This article has no abstract
Epistemonikos ID: 62e1329f85f0158901f1c6ee92c48c74ca24c536
First added on: Feb 14, 2025